Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: Further analyses from the LUME-Lung 1 study by Heigener, D. et al.
Efficacy and safety of nintedanib (NIN)/docetaxel (DOC) in patients with lung adenocarcinoma: 
Further analyses from the LUME-Lung 1 study 
D. Heigener, M. Gottfried, J. Bennouna, I. Bondarenko, J-Y. Douillard, M. Krzakowski, A. Mellemgaard, S. 
Novello, S. Orlov, Y.J. Summers 
Ann Oncol (2016) 27 (suppl_6): 1276P. 
DOI: https://doi.org/10.1093/annonc/mdw383.76 
Published: 11 October 2016 
Background: NIN is a triple angiokinase inhibitor approved in the EU in combination with DOC for the 
treatment of adenocarcinoma non-small cell lung cancer patients after first-line therapy (FLT). A 
continuous linear correlation between overall survival (OS) benefit with NIN and the predictive marker 
“time from start of FLT” (TSFLT) has been observed in adenocarcinoma patients. 
Methods: First, analyses were conducted of European adenocarcinoma patients, who comprise the 
majority of the population from the Phase III LUME-Lung 1 trial comparing NIN/DOC with placebo 
(PLA)/DOC (NCT00805194). Second, in order to further characterise time from FLT, analyses were 
conducted in adenocarcinoma populations defined by the dichotomisation at appropriate cut-points of 
TSFLT or progressive disease (PD) as best response to FLT. Analyses based on “time from end... 
Issue Section: 
 Submitted abstracts 
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical 
Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 
You do not currently have access to this article. 
 
